Fungal Infection Testing + Diagnostics for Human Health

Since 2002, MiraVista Diagnostics has been developing and evolving our menu of diagnostic tests for fungal infections. We work with hospital labs, research university labs, government and municipal labs, physician practices, large reference labs and CROs across the country to detect, analyze and monitor a wide range of serious mycology infections that afflict their patients. This includes antigen and antibody detection tests for aspergillus, blastomyces dermatitidis, histoplasma capsulatum, coccidioides, cryptococcus and beta-D-glucan.

Accurate Test Results Lead to Better Patient Outcomes

MiraVista Diagnostics understands the critical role we play in the health care and health science continuum. Because we take that responsibility seriously, we are committed to partnering with clinicians to consistently deliver:

  • Superior clinical standards in testing accuracy and sensitivity
  • Rapid response and test results
  • Dedication to excellent client service and customer satisfaction
  • Direct access to our infectious disease experts
  • Quality assurance across our organization
  • Compliance with regulatory mandates and industry best practices
  • Continuous product and service improvement
Company News

ALERT: Thanksgiving Holiday Schedule: Office & Lab CLOSED Thursday, November 23

MiraVista Diagnostics’ office and laboratory will be CLOSED for Thanksgiving on Thursday, November 23, 2017. Please keep our holiday schedule in mind when you are shipping specimens or requesting diagnostic test results. We will re-open Friday, November 24 and operate…
READ MORE →

MiraVista Diagnostics is Participating in 2017 ID Week in San Diego

MiraVista Diagnostics is participating in 2017 ID Week in San Diego on October 4-8, 2017. Representatives from the company’s clinical laboratory team will be available to discuss our latest mycology research and menu of diagnostic tests for serious fungal infections….
READ MORE →

MiraVista Diagnostics Supports Fungal Disease Awareness Week

August 14–18, 2017, is the first Fungal Disease Awareness Week. CDC and partners have organized this week to highlight the importance of recognizing serious fungal diseases early enough in the course of a patient’s illness to provide life-saving treatment. MiraVista…
READ MORE →

MiraVista is Participating in the 2017 Coccidioidomycosis Study Group Symposium

MiraVista Diagnostics is participating in the 2017 Coccidioidomycosis Study Group Symposium on August 11-13 at the Stanford University Medical School. Representatives from the company’s clinical laboratory will be available to discuss MiraVista’s menu of diagnostic tests for serious fungal infections….
READ MORE →

NEW: MVista® Histoplasma Antibody IgG IgM EIA

Improve Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen & Antibody Testing Review the technical specifications for the NEW MVista® Histoplasma Antibody IgG IgM EIA>> CLINICAL BACKGROUND Acute pulmonary histoplasmosis (APH) can be severe, especially following heavy exposure and is…
READ MORE →

BULLETIN: CSTE Revised Its Histoplasmosis Position Statement at the 2016 Annual Conference

The Council of State and Territorial Epidemiologists (CSTE) approved the Infectious Disease Committee’s revisions to the histoplasmosis position statement, “Standardized Surveillance Case Definition for Histoplasmosis” at the organization’s annual conference in Anchorage, Alaska on June 19-23, 2016. Review the revised…
READ MORE →

LEARN MORE
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo